Clinical pretreatment risk factors and Ga‐67 scintigraphy early during treatment for prediction of outcome of patients with aggressive non‐Hodgkin lymphoma
Ora Israel(Technion – Israel Institute of Technology), Dov Front(Rambam Health Care Campus), Maya Mor(Rambam Health Care Campus), Nissim Haim(Technion – Israel Institute of Technology), Eldad J. Dann(Rambam Health Care Campus), Alex Frenkel(Girls Incorporated), Ron Epelbaum(University of Bern), Diana Gaitini(Technion – Israel Institute of Technology), Gerald M. Kolodny(Beth Israel Deaconess Medical Center), Rachel Bar‐Shalom(Rambam Health Care Campus)
Cited by 31
Related Papers
Activation of Human Brown Adipose Tissue by a β3-Adrenergic Receptor Agonist
|Cell Metabolism|2015|1k
Curcumin as an Anti-Cancer Agent: Review of the Gap Between Basic and Clinical Applications
|Current Medicinal Chemistry|2009|480
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
|British Journal of Cancer|2014|444
<sup>18</sup>F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients
|Journal of Nuclear Medicine|2009|381
Curcumin and Gemcitabine in Patients With Advanced Pancreatic Cancer
|Nutrition and Cancer|2010|279